Use of TCTP as biomarker for predicting efficacy, prognosis of immunotherapy or resistance thereto, and target of immunotherapy for enhancing efficacy

摘要

The present invention relates to biomarkers for predicting the efficacy, prognosis, or resistance of immunotherapy, and the use of TCTP as a target for enhancing the efficacy of immunotherapy. When using the biomarkers (TCTP, EGFR, AKT, MCL1, and/or CXCL10) of the present invention, it is possible to predict resistance and prognosis to immunotherapy, select a therapy that provides a therapeutic advantage, and to be resistant to immunotherapy It can be usefully used to treat cancer or tumors with .